作者
Nathalie Talbodec, Pauline Le Roy, Peggy Fournier, Benoit Lesage, Elodie Lepoutre, François Castex, Jean Michel Godchaux, Lionel Vandeville, Benjamin Bismuth, Xavier Lesage, Pauline Bayart, Michael Genin, Christel Rousseaux, Veronique Maquet, Salvatore Modica, Pierre Desreumaux, Caroline Valibouze
发表日期
2024/5/5
期刊
World Journal of Gastrointestinal Pharmacology and Therapeutics
卷号
15
期号
3
出版商
Baishideng Publishing Group Inc
简介
BACKGROUND
Irritable bowel syndrome (IBS), defined according to the Rome IV diagnostic criteria, is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain related to altered bowel habits. First-line recommended treatments are limited to combining drugs targeting predominant symptoms, particularly pain (antispasmodics), constipation (laxatives), and diarrhea (loperamide), yielding only a limited therapeutic gain. GASTRAP® DIRECT is a class IIa medical formulation composed of a combination of chitin-glucan and simethicone indicated for the symptomatic treatment of gas-related gastrointestinal disorders by combining different mechanisms of action.
AIM
To evaluate the efficacy, tolerability, and safety of 4-week GASTRAP® DIRECT treatment in patients with IBS.
METHODS
In this prospective, multicenter, open-label trial, 120 patients with IBS received three sticks of GASTRAP® …
学术搜索中的文章
N Talbodec, P Le Roy, P Fournier, B Lesage… - World Journal of Gastrointestinal Pharmacology and …, 2024